{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:21:45Z","timestamp":1791908505200,"version":"4.3.4"},"reference-count":178,"publisher":"Portland Press Ltd.","issue":"8","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,4,1]]},"abstract":"<jats:p>RA (rheumatoid arthritis) is a chronic rheumatic condition hallmarked by joint inflammation and destruction by self-reactive immune responses. Clinical management of RA patients is often hampered by its heterogeneous nature in both clinical presentation and outcome, thereby highlighting the need for new predictive biomarkers. In this sense, several studies have recently revealed a role for type\u00a0I IFNs (interferons), mainly IFN\u03b1, in the pathogenesis of a subset of RA patients. Genetic variants associated with the type\u00a0I IFN pathway have been linked with RA development, as well as with clinical features. Moreover, a role for IFN\u03b1 as a trigger for RA development has also been described. Additionally, a type\u00a0I IFN signature has been associated with the early diagnosis of RA and clinical outcome prediction in patients undergoing biological drug treatment, two challenging issues for decision-making in the clinical setting. Moreover, these cytokines have been related to endothelial damage and vascular repair failure in different autoimmune disorders. Therefore, together with chronic inflammation and disease features, they could probably account for the increased cardiovascular disease morbidity and mortality of these patients. The main aim of the present review is to provide recent evidence supporting a role for type\u00a0I IFNs in the immunopathology of RA, as well as to analyse their possible role as biomarkers for disease management.<\/jats:p>","DOI":"10.1042\/cs20140554","type":"journal-article","created":{"date-parts":[[2014,12,23]],"date-time":"2014-12-23T15:36:23Z","timestamp":1419348983000},"page":"449-464","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Type I IFNs as biomarkers in rheumatoid arthritis: towards disease profiling and personalized medicine"],"prefix":"10.1042","volume":"128","author":[{"given":"Javier","family":"Rodr\u00edguez-Carrio","sequence":"first","affiliation":[{"name":"Area of Immunology, Department of Functional Biology, University of Oviedo, Asturias, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"L\u00f3pez","sequence":"additional","affiliation":[{"name":"Area of Immunology, Department of Functional Biology, University of Oviedo, Asturias, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Su\u00e1rez","sequence":"additional","affiliation":[{"name":"Area of Immunology, Department of Functional Biology, University of Oviedo, Asturias, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2014,12,23]]},"reference":[{"key":"2021113010371260600_B1","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type\u00a0I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"2021113010371260600_B2","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1126\/science.284.5421.1835","article-title":"The nature of the principal type\u00a01 interferon-producing cells in human blood","volume":"284","author":"Siegal","year":"1999","journal-title":"Science"},{"key":"2021113010371260600_B3","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.immuni.2006.08.010","article-title":"Type I interferon in systemic lupus erythematosus and other autoimmune diseases","volume":"25","author":"Banchereau","year":"2006","journal-title":"Immunity"},{"key":"2021113010371260600_B4","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.immuni.2006.08.007","article-title":"Type I interferons in host defense","volume":"25","author":"Stetson","year":"2006","journal-title":"Immunity"},{"key":"2021113010371260600_B5","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3109\/03009734.2011.624649","article-title":"The type\u00a0I interferon system in the etiopathogenesis of autoimmune diseases","volume":"116","author":"Ronnblom","year":"2011","journal-title":"Ups. J. Med. Sci."},{"key":"2021113010371260600_B6","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/ar2881","article-title":"Overview of the biology of type\u00a0I interferons","volume":"12","author":"Kalliolias","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"2021113010371260600_B7","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/BOR.0b013e32835c7e32","article-title":"The interferon signature in autoimmune diseases","volume":"25","author":"Ronnblom","year":"2013","journal-title":"Curr. Opin. Rheumatol."},{"key":"2021113010371260600_B8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1749-6632.2011.06220.x","article-title":"Type I interferonopathies: a novel set of inborn errors of immunity","volume":"1238","author":"Crow","year":"2011","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"2021113010371260600_B9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1136\/annrheumdis-2013-eular.30","article-title":"Type I Interferonopathies","volume":"72","author":"Ronnblom","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"2021113010371260600_B10","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1126\/science.6176024","article-title":"Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon","volume":"216","author":"Preble","year":"1982","journal-title":"Science"},{"key":"2021113010371260600_B11","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1191\/096120300674499064","article-title":"Activation of type\u00a0I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies","volume":"9","author":"Bengtsson","year":"2000","journal-title":"Lupus"},{"key":"2021113010371260600_B12","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113010371260600_B13","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/1529-0131(200007)43:7&lt;1431::AID-ANR3&gt;3.0.CO;2-E","article-title":"Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy","volume":"43","author":"Ioannou","year":"2000","journal-title":"Arthritis Rheum."},{"key":"2021113010371260600_B14","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s10067-004-1024-2","article-title":"Systemic lupus erythematosus arising during interferon-\u03b1 therapy for cryoglobulinemic vasculitis associated with hepatitis C","volume":"24","author":"Niewold","year":"2005","journal-title":"Clin. Rheumatol."},{"key":"2021113010371260600_B15","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.4049\/jimmunol.174.5.2499","article-title":"IFN-\u03b1 induces early lethal lupus in preautoimmune (New Zealand Black x New Zealand White) F1 but not in BALB\/c mice","volume":"174","author":"Mathian","year":"2005","journal-title":"J. Immunol."},{"key":"2021113010371260600_B16","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1080\/08916930310001605864","article-title":"Links between type\u00a0I interferons and the genetic basis of disease in mouse lupus","volume":"36","author":"Jorgensen","year":"2003","journal-title":"Autoimmunity"},{"key":"2021113010371260600_B17","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/sj.gene.6364329","article-title":"Genetic susceptibility to polyI:C-induced IFN\u03b1\/\u03b2-dependent accelerated disease in lupus-prone mice","volume":"7","author":"Jorgensen","year":"2006","journal-title":"Genes Immun."},{"key":"2021113010371260600_B18","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.coi.2004.09.014","article-title":"The emerging role of interferon in human systemic lupus erythematosus","volume":"16","author":"Baechler","year":"2004","journal-title":"Curr. Opin. Immunol."},{"key":"2021113010371260600_B19","doi-asserted-by":"publisher","first-page":"5294","DOI":"10.1073\/pnas.0900615106","article-title":"IFN\u03b1 kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model","volume":"106","author":"Zagury","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113010371260600_B20","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.1002\/art.34632","article-title":"Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study","volume":"64","author":"McBride","year":"2012","journal-title":"Arthritis Rheum."},{"key":"2021113010371260600_B21","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1136\/ard.2010.144485","article-title":"Safety profile and clinical activity of sifalimumab, a fully human anti-interferon \u03b1 monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study","volume":"70","author":"Merrill","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"2021113010371260600_B22","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1126\/stke.4162007pe70","article-title":"Type I interferons as anti-inflammatory mediators","volume":"2007","author":"Benveniste","year":"2007","journal-title":"Sci. STKE."},{"key":"2021113010371260600_B23","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.antiviral.2006.03.006","article-title":"Anti-inflammatory properties of Type\u00a0I interferons","volume":"71","author":"Billiau","year":"2006","journal-title":"Antiviral Res."},{"key":"2021113010371260600_B24","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1093\/rheumatology\/38.4.362","article-title":"The effects of interferon \u03b2 treatment on arthritis","volume":"38","author":"Tak","year":"1999","journal-title":"Rheumatology"},{"key":"2021113010371260600_B25","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/416744a","article-title":"RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-\u03b2","volume":"416","author":"Takayanagi","year":"2002","journal-title":"Nature"},{"key":"2021113010371260600_B26","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/1529-0131(200002)43:2&lt;270::AID-ANR5&gt;3.0.CO;2-H","article-title":"The effects of interferon-\u03b2 treatment of synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis","volume":"43","author":"Smeets","year":"2000","journal-title":"Arthritis Rheum."},{"key":"2021113010371260600_B27","doi-asserted-by":"publisher","first-page":"R239","DOI":"10.1186\/ar1165","article-title":"Treatment with recombinant interferon-\u03b2 reduces inflammation and slows cartilage destruction in the collagen-induced arthritis model of rheumatoid arthritis","volume":"6","author":"van","year":"2004","journal-title":"Arthritis Res. Ther."},{"key":"2021113010371260600_B28","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1136\/ard.2003.020347","article-title":"A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon \u03b2-1a in the treatment of patients with active rheumatoid arthritis","volume":"64","author":"van Holten","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"2021113010371260600_B29","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1136\/ard.2010.141077","article-title":"Interleukin 1 receptor antagonist mediates the beneficial effects of systemic interferon \u03b2 in mice: implications for rheumatoid arthritis","volume":"70","author":"Corr","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"2021113010371260600_B30","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1016\/j.clinthera.2004.12.019","article-title":"Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis","volume":"26","author":"Furst","year":"2004","journal-title":"Clin. Ther."},{"key":"2021113010371260600_B31","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/1477-7525-12-102","article-title":"Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs\u2013a systematic review and network meta-analysis","volume":"12","author":"Jansen","year":"2014","journal-title":"Health Qual. Life Outcomes"},{"key":"2021113010371260600_B32","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1186\/ar2886","article-title":"Type I interferon in organ-targeted autoimmune and inflammatory diseases","volume":"12","author":"Crow","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"2021113010371260600_B33","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/ar4445","article-title":"Understanding IFNlambda in rheumatoid arthritis","volume":"16","author":"de Groen","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"2021113010371260600_B34","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/jid.2010.244","article-title":"Evidence for a pathophysiological role of keratinocyte-derived type\u00a0III interferon (IFNlambda) in cutaneous lupus erythematosus","volume":"131","author":"Zahn","year":"2011","journal-title":"J. Invest Dermatol."},{"key":"2021113010371260600_B35","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1007\/s11033-012-2233-4","article-title":"Associations between interferon regulatory factor 5 polymorphisms and rheumatoid arthritis: a meta-analysis","volume":"40","author":"Lee","year":"2013","journal-title":"Mol. Biol. Rep."},{"key":"2021113010371260600_B36","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1177\/0961203313504479","article-title":"A redundant epistatic interaction between IRF5 and STAT4 of the type\u00a0I interferon pathway in susceptibility to lupus and rheumatoid arthritis","volume":"22","author":"Kim","year":"2013","journal-title":"Lupus"},{"key":"2021113010371260600_B37","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/ard.2007.085704","article-title":"A single nucleotide polymorphism in the IRF5 promoter region is associated with susceptibility to rheumatoid arthritis in the Japanese population","volume":"68","author":"Shimane","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"2021113010371260600_B38","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1172\/JCI119577","article-title":"Genetic bias in immune responses to a cassette shared by different microorganisms in patients with rheumatoid arthritis","volume":"100","author":"La","year":"1997","journal-title":"J. Clin. Invest."},{"key":"2021113010371260600_B39","doi-asserted-by":"publisher","first-page":"5104","DOI":"10.1073\/pnas.86.13.5104","article-title":"Susceptibility to rheumatoid arthritis maps to a T-cell epitope shared by the HLA-Dw4 DR \u03b2-1 chain and the Epstein-Barr virus glycoprotein gp110","volume":"86","author":"Roudier","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113010371260600_B40","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1002\/art.23426","article-title":"Association of interferon regulatory factor 5 haplotypes, similar to that found in systemic lupus erythematosus, in a large subgroup of patients with rheumatoid arthritis","volume":"58","author":"Dieguez-Gonzalez","year":"2008","journal-title":"Arthritis Rheum."},{"key":"2021113010371260600_B41","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1007\/s00296-013-2806-0","article-title":"Association of the IRF5 rs2004640 polymorphism with rheumatoid arthritis: a meta-analysis","volume":"33","author":"Jia","year":"2013","journal-title":"Rheumatol. Int."},{"key":"2021113010371260600_B42","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.1002\/art.22271","article-title":"Analysis of IRF5 gene functional polymorphisms in rheumatoid arthritis","volume":"54","author":"Rueda","year":"2006","journal-title":"Arthritis Rheum."},{"key":"2021113010371260600_B43","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1084\/jem.185.2.231","article-title":"Reduced incidence and severity of antigen-induced autoimmune diseases in mice lacking interferon regulatory factor-1","volume":"185","author":"Tada","year":"1997","journal-title":"J. Exp. Med."},{"key":"2021113010371260600_B44","doi-asserted-by":"publisher","first-page":"797","DOI":"10.3899\/jrheum.100758","article-title":"Autosome-wide copy number variation association analysis for rheumatoid arthritis using the WTCCC high-density SNP genotype data","volume":"38","author":"Uddin","year":"2011","journal-title":"J. Rheumatol."},{"key":"2021113010371260600_B45","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJMoa073003","article-title":"STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus","volume":"357","author":"Remmers","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"2021113010371260600_B46","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.3899\/jrheum.111284","article-title":"Variants within STAT genes reveal association with anticitrullinated protein antibody-negative rheumatoid arthritis in 2 European populations","volume":"39","author":"Seddighzadeh","year":"2012","journal-title":"J. Rheumatol."},{"key":"2021113010371260600_B47","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/ng.2933","article-title":"Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type\u00a0I interferon signaling","volume":"46","author":"Rice","year":"2014","journal-title":"Nat. Genet."},{"key":"2021113010371260600_B48","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3109\/08916934.2013.796937","article-title":"Association of IFIH1 rs1990760 polymorphism with susceptibility to autoimmune diseases: a meta-analysis","volume":"46","author":"Cen","year":"2013","journal-title":"Autoimmunity"},{"key":"2021113010371260600_B49","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1136\/ard.2007.073213","article-title":"Association of the IFIH1-GCA-KCNH7 chromosomal region with rheumatoid arthritis","volume":"67","author":"Martinez","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"2021113010371260600_B50","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00296-013-2666-7","article-title":"Toll-like receptor polymorphisms and rheumatoid arthritis: a systematic review","volume":"34","author":"Lee","year":"2014","journal-title":"Rheumatol. Int."},{"key":"2021113010371260600_B51","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1056\/NEJM197907053010102","article-title":"Immune interferon in the circulation of patients with autoimmune disease","volume":"301","author":"Hooks","year":"1979","journal-title":"N. Engl. J. Med."},{"key":"2021113010371260600_B52","first-page":"88","article-title":"Cytokines in synovial fluid: II. The presence of tumour necrosis factor and interferon","volume":"73","author":"Hopkins","year":"1988","journal-title":"Clin. Exp. Immunol."},{"key":"2021113010371260600_B53","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/rheumatology\/29.4.315","article-title":"Immunoreactive circulating \u03b1-interferon in rheumatoid arthritis","volume":"29","author":"Hasler","year":"1990","journal-title":"Br. J. Rheumatol."},{"key":"2021113010371260600_B54","first-page":"77","article-title":"A sensitive radioimmunoassay for \u03b1-interferon: circulating \u03b1-interferon-like substance in the plasma of healthy individuals and rheumatoid arthritis patients","volume":"66","author":"Shiozawa","year":"1986","journal-title":"Clin. Exp. Immunol."},{"key":"2021113010371260600_B55","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3109\/08916930903510971","article-title":"Type I interferon therapy and its role in autoimmunity","volume":"43","author":"Biggioggero","year":"2010","journal-title":"Autoimmunity"},{"key":"2021113010371260600_B56","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/BOR.0b013e328010c547","article-title":"Syndromes and complications of interferon therapy","volume":"19","author":"Borg","year":"2007","journal-title":"Curr. Opin. Rheumatol."},{"key":"2021113010371260600_B57","first-page":"211","article-title":"Prolonged treatment with interferon \u03b1 and peginterferon induces rheumatoid arthritis syndrome and erythema nodosum","volume":"17","author":"Ionescu","year":"2008","journal-title":"J. Gastrointestin. Liver Dis."},{"key":"2021113010371260600_B58","first-page":"1009","article-title":"Rheumatoid arthritis complicating adjuvant interferon-\u03b1 therapy for malignant melanoma","volume":"26","author":"Johnson","year":"1999","journal-title":"J. Rheumatol."},{"key":"2021113010371260600_B59","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s003930050169","article-title":"Interferon-\u03b1-associated polyarthritis. Possible induction of seropositive rheumatoid arthritis by interferon-\u03b1: two case reports and review of the literature","volume":"58","author":"Kotter","year":"1999","journal-title":"Z. Rheumatol."},{"key":"2021113010371260600_B60","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/S0049-0172(98)80015-2","article-title":"\u03b1-interferon-induced arthritis: clinical presentation treatment, and prevention","volume":"27","author":"Nesher","year":"1998","journal-title":"Semin. Arthritis Rheum."},{"key":"2021113010371260600_B61","first-page":"1844","article-title":"Interferon-\u03b1 associated arthritis","volume":"24","author":"Chung","year":"1997","journal-title":"J. Rheumatol."},{"key":"2021113010371260600_B62","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/PL00011206","article-title":"Rheumatoid arthritis induced by \u03b1-interferon therapy","volume":"20","author":"Passos de","year":"2001","journal-title":"Clin. Rheumatol."},{"key":"2021113010371260600_B63","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1186\/1756-0500-6-437","article-title":"Rheumatoid arthritis following PEG-interferon-\u03b1-2a plus ribavirin treatment for chronic hepatitis C: a case report and review of the literature","volume":"6","author":"Cacopardo","year":"2013","journal-title":"BMC Res. Notes"},{"key":"2021113010371260600_B64","first-page":"228","article-title":"Rheumatoid arthritis: a complication of interferon therapy","volume":"87","author":"Nadir","year":"1994","journal-title":"J. Okla. State Med. Assoc."},{"key":"2021113010371260600_B65","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.3899\/jrheum.100092","article-title":"Development of anti-CCP-positive rheumatoid arthritis following pegylated interferon-\u03b12a treatment for chronic hepatitis C infection","volume":"37","author":"Yang","year":"2010","journal-title":"J. Rheumatol."},{"key":"2021113010371260600_B66","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/00002281-200107000-00010","article-title":"Infectious agents in chronic rheumatic diseases","volume":"13","author":"Hyrich","year":"2001","journal-title":"Curr. Opin. Rheumatol."},{"key":"2021113010371260600_B67","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.berh.2006.08.007","article-title":"Infection and musculoskeletal conditions: viral causes of arthritis","volume":"20","author":"Franssila","year":"2006","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"2021113010371260600_B68","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/sj.gene.6364438","article-title":"Expression of a pathogen-response program in peripheral blood cells defines a subgroup of rheumatoid arthritis patients","volume":"9","author":"van der Pouw Kraan","year":"2008","journal-title":"Genes Immun."},{"key":"2021113010371260600_B69","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/nature05245","article-title":"Chronic polyarthritis caused by mammalian DNA that escapes from degradation in macrophages","volume":"443","author":"Kawane","year":"2006","journal-title":"Nature"},{"key":"2021113010371260600_B70","doi-asserted-by":"publisher","first-page":"5656","DOI":"10.4049\/jimmunol.172.9.5656","article-title":"Arthritogenic properties of double-stranded (viral) RNA","volume":"172","author":"Zare","year":"2004","journal-title":"J. Immunol."},{"key":"2021113010371260600_B71","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/art.21517","article-title":"Requirement of type\u00a0I interferon signaling for arthritis triggered by double-stranded RNA","volume":"54","author":"Magnusson","year":"2006","journal-title":"Arthritis Rheum."},{"key":"2021113010371260600_B72","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1126\/science.1093616","article-title":"Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA","volume":"303","author":"Diebold","year":"2004","journal-title":"Science"},{"key":"2021113010371260600_B73","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S1568-9972(02)00101-5","article-title":"Dosage and characterization of circulating DNA: present usage and possible applications in systemic autoimmune disorders","volume":"2","author":"Galeazzi","year":"2003","journal-title":"Autoimmun. Rev."},{"key":"2021113010371260600_B74","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/art.24390","article-title":"Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis","volume":"61","author":"Lopez-Longo","year":"2009","journal-title":"Arthritis Rheum."},{"key":"2021113010371260600_B75","doi-asserted-by":"publisher","first-page":"3237","DOI":"10.1002\/eji.200838362","article-title":"Arthritogenic dsRNA is present in synovial fluid from rheumatoid arthritis patients with an erosive disease course","volume":"38","author":"Bokarewa","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"2021113010371260600_B76","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1172\/JCI107165","article-title":"The occurrence of single-stranded DNA in the serum of patients with systemic lupus erythematosus and other diseases","volume":"52","author":"Koffler","year":"1973","journal-title":"J. Clin. Invest."},{"key":"2021113010371260600_B77","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1136\/ard.2007.086421","article-title":"Type I interferons might form the link between Toll-like receptor (TLR) 3\/7 and TLR4-mediated synovial inflammation in rheumatoid arthritis (RA)","volume":"68","author":"Roelofs","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"2021113010371260600_B78","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/art.1780390202","article-title":"Presentation of self peptides by dendritic cells: possible implications for the pathogenesis of rheumatoid arthritis","volume":"39","author":"Thomas","year":"1996","journal-title":"Arthritis Rheum."},{"key":"2021113010371260600_B79","doi-asserted-by":"publisher","first-page":"R15","DOI":"10.1186\/ar1864","article-title":"Enumeration and phenotypical analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritis","volume":"8","author":"Jongbloed","year":"2006","journal-title":"Arthritis Res. Ther."},{"key":"2021113010371260600_B80","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.4049\/jimmunol.156.8.3074","article-title":"Functional differentiation of dendritic cells in rheumatoid arthritis: role of CD86\u00a0in the synovium","volume":"156","author":"Thomas","year":"1996","journal-title":"J. Immunol."},{"key":"2021113010371260600_B81","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113010371260600_B82","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1136\/ard.2011.150326","article-title":"Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type\u00a0I interferon pathway","volume":"70","author":"Higgs","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"2021113010371260600_B83","doi-asserted-by":"publisher","first-page":"R112","DOI":"10.1186\/ar2510","article-title":"Association of elevated transcript levels of interferon-inducible chemokines with disease activity and organ damage in systemic lupus erythematosus patients","volume":"10","author":"Fu","year":"2008","journal-title":"Arthritis Res. Ther."},{"key":"2021113010371260600_B84","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1136\/ard.2003.017194","article-title":"A gene expression signature for recent onset rheumatoid arthritis in peripheral blood mononuclear cells","volume":"63","author":"Olsen","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"2021113010371260600_B85","doi-asserted-by":"publisher","first-page":"e24828","DOI":"10.1371\/journal.pone.0024828","article-title":"Importance of correlation between gene expression levels: application to the type\u00a0I interferon signature in rheumatoid arthritis","volume":"6","author":"Reynier","year":"2011","journal-title":"PLoS. ONE"},{"key":"2021113010371260600_B86","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1007\/s00109-012-0907-y","article-title":"The multifaceted balance of TNF-\u03b1 and type\u00a0I\/II interferon responses in SLE and RA: how monocytes manage the impact of cytokines","volume":"90","author":"Smiljanovic","year":"2012","journal-title":"J. Mol. Med."},{"key":"2021113010371260600_B87","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1136\/ard.2006.063412","article-title":"Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type\u00a0I interferon signature in a subpopulation of patients","volume":"66","author":"van der Pouw Kraan","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"2021113010371260600_B88","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1002\/art.22578","article-title":"Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus","volume":"56","author":"Nzeusseu","year":"2007","journal-title":"Arthritis Rheum."},{"key":"2021113010371260600_B89","doi-asserted-by":"publisher","first-page":"e37000","DOI":"10.1371\/journal.pone.0037000","article-title":"Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients","volume":"7","author":"Somers","year":"2012","journal-title":"PLoS. ONE"},{"key":"2021113010371260600_B90","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1002\/art.34544","article-title":"The interferon signature and STAT1 expression in rheumatoid arthritis synovial fluid macrophages are induced by tumor necrosis factor \u03b1 and counter-regulated by the synovial fluid microenvironment","volume":"64","author":"Gordon","year":"2012","journal-title":"Arthritis Rheum."},{"key":"2021113010371260600_B91","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/ni1576","article-title":"TNF activates an IRF1-dependent autocrine loop leading to sustained expression of chemokines and STAT1-dependent type\u00a0I interferon-response genes","volume":"9","author":"Yarilina","year":"2008","journal-title":"Nat. Immunol."},{"key":"2021113010371260600_B92","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1136\/annrheumdis-2012-202753","article-title":"The type\u00a0I IFN signature as a biomarker of preclinical rheumatoid arthritis","volume":"72","author":"Lubbers","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"2021113010371260600_B93","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/art.27294","article-title":"Gene expression profiling in autoantibody-positive patients with arthralgia predicts development of arthritis","volume":"62","author":"van Baarsen","year":"2010","journal-title":"Arthritis Rheum."},{"key":"2021113010371260600_B94","doi-asserted-by":"publisher","first-page":"R11","DOI":"10.1186\/ar2912","article-title":"Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment","volume":"12","author":"van Baarsen","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"2021113010371260600_B95","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1093\/rheumatology\/ken083","article-title":"Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-\u03b1 monoclonal antibody, infliximab","volume":"47","author":"Sekiguchi","year":"2008","journal-title":"Rheumatology"},{"key":"2021113010371260600_B96","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1093\/rheumatology\/kep345","article-title":"Type I interferons have no major influence on humoral autoimmunity in rheumatoid arthritis","volume":"49","author":"Cantaert","year":"2010","journal-title":"Rheumatology"},{"key":"2021113010371260600_B97","article-title":"Interferon gene expression signature in rheumatoid arthritis neutrophils correlates with a good response to TNFi therapy","author":"Wright","year":"2014","journal-title":"Rheumatology"},{"key":"2021113010371260600_B98","doi-asserted-by":"publisher","first-page":"R95","DOI":"10.1186\/ar3819","article-title":"The interferon type\u00a0I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients","volume":"14","author":"Raterman","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"2021113010371260600_B99","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.1002\/art.27702","article-title":"Relationship between the type\u00a0I interferon signature and the response to rituximab in rheumatoid arthritis patients","volume":"62","author":"Thurlings","year":"2010","journal-title":"Arthritis Rheum."},{"key":"2021113010371260600_B100","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1136\/annrheumdis-2011-201115","article-title":"Pretreatment synovial transcriptional profile is associated with early and late clinical response in rheumatoid arthritis patients treated with rituximab","volume":"71","author":"Hogan","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"2021113010371260600_B101","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1136\/ard.2010.147199","article-title":"Pharmacological induction of interferon type\u00a0I activity following treatment with rituximab determines clinical response in rheumatoid arthritis","volume":"70","author":"Vosslamber","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"2021113010371260600_B102","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/art.21650","article-title":"Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse","volume":"54","author":"Cambridge","year":"2006","journal-title":"Arthritis Rheum."},{"key":"2021113010371260600_B103","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1136\/annrheumdis-2012-201381","article-title":"Prevalence of interferon type\u00a0I signature in CD14 monocytes of patients with Sjogren's syndrome and association with disease activity and BAFF gene expression","volume":"72","author":"Brkic","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"2021113010371260600_B104","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1177\/1352458510393771","article-title":"Interferon-\u03b2 increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production","volume":"17","author":"Hedegaard","year":"2011","journal-title":"Mult. Scler."},{"key":"2021113010371260600_B105","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1093\/rheumatology\/keu249","article-title":"IFNa-induced BLyS expression and mobilization in healthy and SLE monocytes","volume":"53","author":"Lopez","year":"2014","journal-title":"Rheumatology"},{"key":"2021113010371260600_B106","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1002\/art.38400","article-title":"Prediction of therapeutic responses to tocilizumab in patients with rheumatoid arthritis\u2013biomarkers identified by analyses of gene expression in peripheral blood mononuclear cells using genome-wide DNA microarray","volume":"66","author":"Sanayama","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"2021113010371260600_B107","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1093\/brain\/awp228","article-title":"A type\u00a0I interferon signature in monocytes is associated with poor response to interferon-\u03b2 in multiple sclerosis","volume":"132","author":"Comabella","year":"2009","journal-title":"Brain"},{"key":"2021113010371260600_B108","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/art.27226","article-title":"Association of the response to tumor necrosis factor antagonists with plasma type\u00a0I interferon activity and interferon-\u03b2\/\u03b1 ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort","volume":"62","author":"Mavragani","year":"2010","journal-title":"Arthritis Rheum."},{"key":"2021113010371260600_B109","first-page":"934","article-title":"Therapeutic implications for interferon-\u03b1 in arthritis: a pilot study","volume":"30","author":"Wong","year":"2003","journal-title":"J. Rheumatol."},{"key":"2021113010371260600_B110","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1136\/ard.2005.040477","article-title":"Expression of interferon \u03b2 in synovial tissue from patients with rheumatoid arthritis: comparison with patients with osteoarthritis and reactive arthritis","volume":"64","author":"van Holten","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"2021113010371260600_B111","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.cellimm.2011.07.014","article-title":"Targeting interferon regulatory factors to inhibit activation of the type\u00a0I IFN response: implications for treatment of autoimmune disorders","volume":"271","author":"Sweeney","year":"2011","journal-title":"Cell. Immunol."},{"key":"2021113010371260600_B112","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1002\/art.22157","article-title":"Antimalarial agents: closing the gate on Toll-like receptors?","volume":"54","author":"Lafyatis","year":"2006","journal-title":"Arthritis Rheum."},{"key":"2021113010371260600_B113","doi-asserted-by":"publisher","first-page":"R155","DOI":"10.1186\/ar3895","article-title":"Hydroxychloroquine is associated with impaired interferon-\u03b1 and tumor necrosis factor-\u03b1 production by plasmacytoid dendritic cells in systemic lupus erythematosus","volume":"14","author":"Sacre","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"2021113010371260600_B114","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1177\/0961203312437270","article-title":"Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort","volume":"21","author":"Willis","year":"2012","journal-title":"Lupus"},{"key":"2021113010371260600_B115","first-page":"87","article-title":"Effect of antimalarial treatment on circulating immune complexes in rheumatoid arthritis","volume":"12","author":"Segal-Eiras","year":"1985","journal-title":"J. Rheumatol."},{"key":"2021113010371260600_B116","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/416603a","article-title":"Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors","volume":"416","author":"Leadbetter","year":"2002","journal-title":"Nature"},{"key":"2021113010371260600_B117","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/rheumatology\/kei282","article-title":"Chloroquine inhibits production of TNF-\u03b1, IL-1\u03b2 and IL-6 from lipopolysaccharide-stimulated human monocytes\/macrophages by different modes","volume":"45","author":"Jang","year":"2006","journal-title":"Rheumatology"},{"key":"2021113010371260600_B118","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1002\/art.21273","article-title":"RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3","volume":"52","author":"Brentano","year":"2005","journal-title":"Arthritis Rheum."},{"key":"2021113010371260600_B119","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.7326\/0003-4819-119-11-199312010-00002","article-title":"Hydroxychloroquine compared with placebo in rheumatoid arthritis. A randomized controlled trial","volume":"119","author":"Clark","year":"1993","journal-title":"Ann. Intern. Med."},{"key":"2021113010371260600_B120","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1136\/annrheumdis-2013-203756","article-title":"The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells","volume":"73","author":"Kubo","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"2021113010371260600_B121","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1136\/ard.2011.150284","article-title":"The JAK inhibitor CP-690, 550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type\u00a0I interferon","volume":"71","author":"Rosengren","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"2021113010371260600_B122","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1002\/art.24557","article-title":"Neutralization of interferon-\u03b1\/\u03b2-inducible genes and downstream effect in a phase I trial of an anti-interferon-\u03b1 monoclonal antibody in systemic lupus erythematosus","volume":"60","author":"Yao","year":"2009","journal-title":"Arthritis Rheum."},{"key":"2021113010371260600_B123","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1136\/annrheumdis-2012-202794","article-title":"A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-\u03b1 monoclonal antibody, shows target neutralisation of a type\u00a0I IFN signature in blood of dermatomyositis and polymyositis patients","volume":"73","author":"Higgs","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"2021113010371260600_B124","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1093\/rheumatology\/ket413","article-title":"Suppression of soluble T cell-associated proteins by an anti-interferon-\u03b1 monoclonal antibody in adult patients with dermatomyositis or polymyositis","volume":"53","author":"Guo","year":"2014","journal-title":"Rheumatology"},{"key":"2021113010371260600_B125","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1186\/ar2887","article-title":"Use of type\u00a0I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFN\u03b1 antibody, in systemic lupus erythematosus","volume":"12","author":"Yao","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"2021113010371260600_B126","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1136\/annrheumdis-2012-202743","article-title":"The potential use of expression profiling: implications for predicting treatment response in rheumatoid arthritis","volume":"72","author":"Smith","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"2021113010371260600_B127","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1136\/annrheumdis-2011-200726","article-title":"Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies","volume":"71","author":"Avina-Zubieta","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"2021113010371260600_B128","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/1529-0131(200112)44:12&lt;2737::AID-ART460&gt;3.0.CO;2-#","article-title":"High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors","volume":"44","author":"del Rincon","year":"2001","journal-title":"Arthritis Rheum."},{"key":"2021113010371260600_B129","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrrheum.2011.75","article-title":"Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE","volume":"7","author":"Symmons","year":"2011","journal-title":"Nat. Rev. Rheumatol."},{"key":"2021113010371260600_B130","doi-asserted-by":"publisher","first-page":"R131","DOI":"10.1186\/ar3442","article-title":"Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study","volume":"13","author":"Innala","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"2021113010371260600_B131","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/art.22482","article-title":"HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis","volume":"57","author":"Gonzalez-Gay","year":"2007","journal-title":"Arthritis Rheum."},{"key":"2021113010371260600_B132","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1161\/01.CIR.0000099844.31524.05","article-title":"Explaining how \u201chigh-grade\u201d systemic inflammation accelerates vascular risk in rheumatoid arthritis","volume":"108","author":"Sattar","year":"2003","journal-title":"Circulation"},{"key":"2021113010371260600_B133","first-page":"2562","article-title":"Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset","volume":"26","author":"Wallberg-Jonsson","year":"1999","journal-title":"J. Rheumatol."},{"key":"2021113010371260600_B134","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1177\/0961203309353773","article-title":"Lupus-prone New Zealand Black\/New Zealand White F1 mice display endothelial dysfunction and abnormal phenotype and function of endothelial progenitor cells","volume":"19","author":"Thacker","year":"2010","journal-title":"Lupus"},{"key":"2021113010371260600_B135","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1002\/art.23035","article-title":"Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus","volume":"56","author":"Lee","year":"2007","journal-title":"Arthritis Rheum."},{"key":"2021113010371260600_B136","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1002\/art.34504","article-title":"Type I interferons modulate vascular function, repair, thrombosis, and plaque progression in murine models of lupus and atherosclerosis","volume":"64","author":"Thacker","year":"2012","journal-title":"Arthritis Rheum."},{"key":"2021113010371260600_B137","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1182\/blood-2007-05-089086","article-title":"Interferon-\u03b1 promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis","volume":"110","author":"Denny","year":"2007","journal-title":"Blood"},{"key":"2021113010371260600_B138","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.4049\/jimmunol.1001782","article-title":"The detrimental effects of IFN-\u03b1 on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction","volume":"185","author":"Thacker","year":"2010","journal-title":"J. Immunol."},{"key":"2021113010371260600_B139","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1093\/rheumatology\/kes152","article-title":"Circulating endothelial cells and their progenitors in systemic lupus erythematosus and early rheumatoid arthritis patients","volume":"51","author":"Rodriguez-Carrio","year":"2012","journal-title":"Rheumatology"},{"key":"2021113010371260600_B140","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1159\/000080748","article-title":"Interferon-\u03b1: regulatory effects on cell cycle and angiogenesis","volume":"80","author":"Rosewicz","year":"2004","journal-title":"Neuroendocrinology"},{"key":"2021113010371260600_B141","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s00432-004-0615-2","article-title":"Interferon \u03b1 2a down-regulates VEGF expression through PI3 kinase and MAP kinase signaling pathways","volume":"131","author":"Wu","year":"2005","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"2021113010371260600_B142","doi-asserted-by":"publisher","first-page":"e86069","DOI":"10.1371\/journal.pone.0086069","article-title":"IFN\u03b1 serum levels are associated with endothelial progenitor cells imbalance and disease features in rheumatoid arthritis patients","volume":"9","author":"Rodriguez-Carrio","year":"2014","journal-title":"PLoS. ONE"},{"key":"2021113010371260600_B143","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2013-205124.74","article-title":"Angiogenic T cells are decreased in rheumatoid arthritis patients","author":"Rodriguez-Carrio","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"2021113010371260600_B144","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1161\/CIRCULATIONAHA.107.694778","article-title":"Identification of a novel role of T cells in postnatal vasculogenesis: characterization of endothelial progenitor cell colonies","volume":"116","author":"Hur","year":"2007","journal-title":"Circulation"},{"key":"2021113010371260600_B145","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1161\/CIRCULATIONAHA.107.697789","article-title":"Synergistic proinflammatory effects of the antiviral cytokine interferon-\u03b1 and Toll-like receptor 4 ligands in the atherosclerotic plaque","volume":"116","author":"Niessner","year":"2007","journal-title":"Circulation"},{"key":"2021113010371260600_B146","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/art.30161","article-title":"How does interferon-\u03b1 insult the vasculature? Let me count the ways","volume":"63","author":"Kaplan","year":"2011","journal-title":"Arthritis Rheum."},{"key":"2021113010371260600_B147","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1182\/blood-2010-03-274605","article-title":"Platelet transcriptional profile and protein expression in patients with systemic lupus erythematosus: up-regulation of the type\u00a0I interferon system is strongly associated with vascular disease","volume":"116","author":"Lood","year":"2010","journal-title":"Blood"},{"key":"2021113010371260600_B148","doi-asserted-by":"publisher","first-page":"33515","DOI":"10.1074\/jbc.M701846200","article-title":"A novel role of the interferon-inducible protein IFI16 as inducer of proinflammatory molecules in endothelial cells","volume":"282","author":"Caposio","year":"2007","journal-title":"J. Biol. Chem."},{"key":"2021113010371260600_B149","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jaut.2010.04.001","article-title":"The proapoptotic activity of the Interferon-inducible gene IFI16 provides new insights into its etiopathogenetic role in autoimmunity","volume":"35","author":"Gugliesi","year":"2010","journal-title":"J. Autoimmun."},{"key":"2021113010371260600_B150","doi-asserted-by":"publisher","first-page":"e63045","DOI":"10.1371\/journal.pone.0063045","article-title":"Nuclear DNA sensor IFI16 as circulating protein in autoimmune diseases is a signal of damage that impairs endothelial cells through high-affinity membrane binding","volume":"8","author":"Gugliesi","year":"2013","journal-title":"PLoS. ONE"},{"key":"2021113010371260600_B151","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.cellimm.2009.02.007","article-title":"Role of the interferon-inducible IFI16 gene in the induction of ICAM-1 by TNF-\u03b1","volume":"257","author":"Sponza","year":"2009","journal-title":"Cell. Immunol."},{"key":"2021113010371260600_B152","doi-asserted-by":"publisher","first-page":"501","DOI":"10.4103\/2045-8932.105039","article-title":"Endothelin-1 as a mediator and potential biomarker for interferon induced pulmonary toxicity","volume":"2","author":"George","year":"2012","journal-title":"Pulm. Circ."},{"key":"2021113010371260600_B153","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1161\/CIRCRESAHA.114.302221","article-title":"Evidence for the involvement of type\u00a0I interferon in pulmonary arterial hypertension","volume":"114","author":"George","year":"2014","journal-title":"Circ. Res."},{"key":"2021113010371260600_B154","first-page":"51","article-title":"Serum and synovial fluid concentrations of endothelin-1\u00a0in patients with rheumatoid arthritis","volume":"30","author":"Haq","year":"1999","journal-title":"J. Med."},{"key":"2021113010371260600_B155","first-page":"CR616\u2013CR619","article-title":"Elevated plasma endothelin-1 levels and vascular dysregulation in patients with rheumatoid arthritis","volume":"8","author":"Pache","year":"2002","journal-title":"Med. Sci. Monit."},{"key":"2021113010371260600_B156","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/s10067-005-0007-2","article-title":"A study on vascular endothelial growth factor and endothelin-1\u00a0in patients with extra-articular involvement of rheumatoid arthritis","volume":"25","author":"Kuryliszyn-Moskal","year":"2006","journal-title":"Clin. Rheumatol."},{"key":"2021113010371260600_B157","doi-asserted-by":"publisher","first-page":"701","DOI":"10.3899\/jrheum.110751","article-title":"Infliximab treatment increases left ventricular ejection fraction in patients with rheumatoid arthritis: assessment of heart function by echocardiography, endothelin 1, interleukin 6, and NT-pro brain natriuretic peptide","volume":"39","author":"Kotyla","year":"2012","journal-title":"J. Rheumatol."},{"key":"2021113010371260600_B158","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1161\/CIRCGENETICS.113.000044","article-title":"Coronary heart disease in systemic lupus erythematosus is associated with interferon regulatory factor-8 gene variants","volume":"6","author":"Leonard","year":"2013","journal-title":"Circ. Cardiovasc. Genet."},{"key":"2021113010371260600_B159","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1089\/dna.2009.0929","article-title":"Association between IRF-5 polymorphisms and risk of acute coronary syndrome","volume":"29","author":"Fan","year":"2010","journal-title":"DNA Cell Biol."},{"key":"2021113010371260600_B160","doi-asserted-by":"publisher","first-page":"A34","DOI":"10.1136\/annrheumdis-2013-205124.76","article-title":"Interferon regulatory factor 5 (IRF5) gene variant rs2004640 is associated with carotid intima media thickness in Rheumatoid Arthritis patients","volume":"73","author":"Vosslamber","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"2021113010371260600_B161","doi-asserted-by":"publisher","first-page":"R146","DOI":"10.1186\/ar4608","article-title":"Interferon regulatory factor 5 genetic variants are associated with cardiovascular disease in patients with rheumatoid arthritis","volume":"16","author":"Garcia-Bermudez","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"2021113010371260600_B162","doi-asserted-by":"publisher","first-page":"567","DOI":"10.2165\/00002018-200629070-00003","article-title":"Heart failure induced by non-cardiac drugs","volume":"29","author":"Slordal","year":"2006","journal-title":"Drug Saf"},{"key":"2021113010371260600_B163","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1536\/ihj.37.905","article-title":"Adverse effects of interferon on the cardiovascular system in patients with chronic hepatitis C","volume":"37","author":"Teragawa","year":"1996","journal-title":"Jpn Heart J."},{"key":"2021113010371260600_B164","first-page":"557","article-title":"Cardiotoxicity of interferon","volume":"99","author":"Sonnenblick","year":"1991","journal-title":"A review of 44 cases. Chest"},{"key":"2021113010371260600_B165","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1093\/rheumatology\/kel449","article-title":"Association of polymorphisms across the tyrosine kinase gene, TYK2\u00a0in UK SLE families","volume":"46","author":"Cunninghame Graham","year":"2007","journal-title":"Rheumatology"},{"key":"2021113010371260600_B166","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/ng.2007.47","article-title":"Polymorphism at the TNF superfamily gene TNFSF4 confers susceptibility to systemic lupus erythematosus","volume":"40","author":"Cunninghame Graham","year":"2008","journal-title":"Nat. Genet."},{"key":"2021113010371260600_B167","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/art.27223","article-title":"Genetic variants and disease-associated factors contribute to enhanced interferon regulatory factor 5 expression in blood cells of patients with systemic lupus erythematosus","volume":"62","author":"Feng","year":"2010","journal-title":"Arthritis Rheum."},{"key":"2021113010371260600_B168","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1093\/hmg\/ddn184","article-title":"A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5","volume":"17","author":"Sigurdsson","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"2021113010371260600_B169","doi-asserted-by":"publisher","first-page":"328","DOI":"10.4238\/2013.February.7.2","article-title":"Meta-analysis demonstrates association between TLR polymorphisms and rheumatoid arthritis","volume":"12","author":"Lee","year":"2013","journal-title":"Genet. Mol. Res."},{"key":"2021113010371260600_B170","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1002\/art.22704","article-title":"Association of a haplotype in the promoter region of the interferon regulatory factor 5 gene with rheumatoid arthritis","volume":"56","author":"Sigurdsson","year":"2007","journal-title":"Arthritis Rheum."},{"key":"2021113010371260600_B171","doi-asserted-by":"publisher","first-page":"e491","DOI":"10.1371\/journal.pmed.0030491","article-title":"Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus","volume":"3","author":"Bauer","year":"2006","journal-title":"PLoS Med."},{"key":"2021113010371260600_B172","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/art.30165","article-title":"Interferon-\u03b1 priming promotes lipid uptake and macrophage-derived foam cell formation: a novel link between interferon-\u03b1 and atherosclerosis in lupus","volume":"63","author":"Li","year":"2011","journal-title":"Arthritis Rheum."},{"key":"2021113010371260600_B173","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/jnci\/81.7.497","article-title":"Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice","volume":"81","author":"Dvorak","year":"1989","journal-title":"J. Natl. Cancer Inst."},{"key":"2021113010371260600_B174","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0165-5728(02)00098-X","article-title":"Interferon-\u03b2 directly influences monocyte infiltration into the central nervous system","volume":"127","author":"Floris","year":"2002","journal-title":"J. Neuroimmunol."},{"key":"2021113010371260600_B175","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1073\/pnas.92.10.4562","article-title":"Interferons \u03b1 and \u03b2 down-regulate the expression of basic fibroblast growth factor in human carcinomas","volume":"92","author":"Singh","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113010371260600_B176","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.3899\/jrheum.080114","article-title":"Putative role of functional interferon regulatory factor 5 (IRF5) polymorphism in rheumatoid arthritis in a Korean population","volume":"35","author":"Kim","year":"2008","journal-title":"J. Rheumatol."},{"key":"2021113010371260600_B177","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s00296-009-1051-z","article-title":"Association between the rs7574865 polymorphism of STAT4 and rheumatoid arthritis: a meta-analysis","volume":"30","author":"Lee","year":"2010","journal-title":"Rheumatol. Int."},{"key":"2021113010371260600_B178","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1002\/1529-0131(199707)40:7&lt;1370::AID-ART30&gt;3.0.CO;2-P","article-title":"Effects of interferon \u03b2-1B in rheumatoid arthritis: a case report","volume":"40","author":"Jabaily","year":"1997","journal-title":"Arthritis Rheum."}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/128\/8\/449\/446830\/cs1280449.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/128\/8\/449\/446830\/cs1280449.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T02:41:38Z","timestamp":1717641698000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/128\/8\/449\/71242\/Type-I-IFNs-as-biomarkers-in-rheumatoid-arthritis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,23]]},"references-count":178,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,4,1]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20140554","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,23]]}}}